142384-07-4 Usage
Description
2-[(3-methyl-4-nitro-2-pyridyl)methylsulfinyl]-1H-benzimidazole, commonly known as omeprazole, is a proton pump inhibitor that plays a crucial role in reducing stomach acid production. This medication is specifically designed to treat various conditions such as gastroesophageal reflux disease (GERD), stomach ulcers, and Zollinger-Ellison syndrome. Omeprazole achieves its therapeutic effect by blocking the enzyme in the stomach wall responsible for acid production, thus lowering the overall acidity level in the stomach. As a widely prescribed medication, it is also available over-the-counter in some countries and is generally well-tolerated with potential side effects like headache, nausea, and diarrhea. It is essential to adhere to the prescribed dosage and treatment duration to minimize the risk of adverse effects.
Uses
Used in Pharmaceutical Industry:
2-[(3-methyl-4-nitro-2-pyridyl)methylsulfinyl]-1H-benzimidazole is used as a therapeutic agent for treating gastrointestinal conditions characterized by excessive stomach acid production. Its application is primarily aimed at alleviating symptoms and promoting healing in patients suffering from GERD, stomach ulcers, and Zollinger-Ellison syndrome. By reducing the amount of acid in the stomach, omeprazole helps manage the discomfort and damage caused by these conditions, improving the patient's quality of life and overall health.
Check Digit Verification of cas no
The CAS Registry Mumber 142384-07-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,2,3,8 and 4 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 142384-07:
(8*1)+(7*4)+(6*2)+(5*3)+(4*8)+(3*4)+(2*0)+(1*7)=114
114 % 10 = 4
So 142384-07-4 is a valid CAS Registry Number.
142384-07-4Relevant articles and documents
An efficient synthesis of dexlansoprazole employing asymmetric oxidation strategy
Raju, Manne Naga,Kumar, Neelam Uday,Reddy, Baddam Sudhakar,Anitha, Naredla,Srinivas, Gangula,Bhattacharya, Apurba,Mukkanti, Kagga,Kolla, Naveenkumar,Bandichhor, Rakeshwar
supporting information; experimental part, p. 5464 - 5466 (2011/11/01)
An alternative and scalable synthesis of dexlansoprazole ((R)-(+)-1); the (R)-enantiomer of Lansoprazole with an enantiomeric excess of >99.8% is presented.
DEXLANSOPRAZOLE PROCESS AND POLYMORPHS
-
Page/Page column 55, (2009/10/22)
Processes for the preparation of dexlansoprazole, an amorphous form of dexlansoprazole, a solid dispersion of amorphous dexlansoprazole and a pharmaceutically acceptable carrier, and processes for their preparation. Also provided are crystalline compounds 2-[(R)-[(4-chloro-3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole and 2-[(R)-[(4-nitro-3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, and methods for their preparation.
